CD79B (US20210261659A1 Biosimilar) Recombinant Monoclonal Antibody

1. CD79B mutations were found in six of 19 cases (31.6%) of primary CNS diffuse large B-cell lymphoma , all in the Y196 mutation hotspot PMID: 28856744
2. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of CD79B mutations. PMID: 28803429
3. hotspot mutations of CD79B Y196 and MYD88 L265 may serve as a genetic hallmark for primary central nervous system lymphoma PMID: 26111727
4. CD79B overexpression leading to activation of AKT/MAPK is a potential mechanism underlying primary ibrutinib resistance in ABC-DLBCL, and support its utility as an effective biomarker to predict therapeutic response to ibrutinib. PMID: 26699656
5. Novel CD79B variations in mature B-cell non-Hodgkin's lymphoma patients were detected. PMID: 27010137
6. MYD88 L265P and CD79B mutations were frequently detected in primary breast diffuse large B-cell lymphoma. PMID: 26752547
7. Oncogenic CD79B mutation is associated with primary diffuse large B-cell lymphomas of central nervous system. PMID: 25347427
8. Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. PMID: 25501023
9. Abberant expression of CD79b in non-B cells caused unwanted reactivity, rendering CD79b unsuitable for T-cell receptor - based immunotherapies. PMID: 25414443
10. results suggest that MYD88 mutations, and to a lesser extent CD79B mutations, are important drivers of lymphomagenesis in PTL PMID: 24253023
11. CD79B and MYD88 mutations are associated with an older age at onset in diffuse large b-cell lymphoma with a significant overlap, which did not affect the outcome of the disease. PMID: 24444466
12. CD79B point mutation is associated with B-cell non-Hodgkin lymphomas. PMID: 23361872
13. Data indicate a secondary promoter located within exon 2 maintained full levels and specificity of hCD79b transcription. PMID: 23649625
14. The present study failed to find any mut-ation in MYD88, CARD11 or CD79B in ocular MALT lymphoma. PMID: 22808296
15. Expression of CD79b is downregulated in both plasma cells and plasma cell myeloma. PMID: 21355953
16. The B cell-specific B29 gene promoter is transactivated in B and non-B cells by cotransfection with the B cell-specific octamer cofactor gene, Bob1 (OCA-B/OBF-1). PMID: 11907094
17. The alternative splicing variant DeltaCD79b may be a powerful modulator of BCR signaling that may play an important role in normal and malignant B cell PMID: 12384401
18. Following B cell receptor cross-linking, a significant amount of the transgenic Ig beta pool (together with Ig alpha) remains on the B cell surface independent of surface immunoglobulin internalization. PMID: 15661909
19. Results reveal tissue-specific patterns of chromatin structures and transcriptional controls at the CD79b/GH locus in B cells distinct from those in the pituitary gland and placenta. PMID: 16847312
20. establish a strong linkage between Igbeta mRNA expression and somatic hypermutation in chronic lymphocytic leukaemia and highlight the complex relationships between biochemical parameters and clinical status in this disease PMID: 17315213
21. Ig-beta was phosphorylated in about 20% of myeloma IgG BCR isolates, but not in normal B-cell controls. PMID: 17701175
22. These results indicate that mutations in Igbeta can cause agammaglobulinemia in man. PMID: 17709424
23. mutations responsible for agammaglobulinemia in humans PMID: 18978465

Show More

Hide All

HGNC: 1699

OMIM: 147245

KEGG: hsa:974

STRING: 9606.ENSP00000376544

UniGene: Hs.89575